Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Non-interventional Post-authorization Safety Study (PASS) of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant ("Transplant Noneligible" [TNE])

NCT03106324 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT03106324
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03106324 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Non-interventional Post-authorization Safety Study (PASS) of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant ("Transplant Noneligible" [TNE])
Lead sponsor
Celgene
Phase
Observational
Overall status
Completed
Start date
March 31, 2017
Completion date
January 14, 2026
Enrollment
911 (actual)
Sites
125

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma